ADMA Biologics Inc (NASDAQ:ADMA) Given Average Recommendation of “Buy” by Brokerages

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have received an average rating of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $11.50.

Several research analysts have issued reports on ADMA shares. Oppenheimer lifted their target price on shares of ADMA Biologics from $14.00 to $16.00 and gave the stock an “outperform” rating in a report on Tuesday, April 2nd. Maxim Group set a $12.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a report on Tuesday, April 2nd. ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. WBB Securities raised shares of ADMA Biologics to a “buy” rating in a report on Thursday, April 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price (up from $10.00) on shares of ADMA Biologics in a report on Monday, April 15th.

In other ADMA Biologics news, major shareholder Life Sciences Maste Perceptive bought 4,000,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was bought at an average cost of $4.00 per share, for a total transaction of $16,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence P. Guiheen bought 25,000 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were acquired at an average price of $4.00 per share, with a total value of $100,000.00. Following the completion of the transaction, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $200,000. The disclosure for this purchase can be found here. Insiders have bought 4,064,500 shares of company stock valued at $16,258,000 over the last three months. 18.80% of the stock is owned by corporate insiders.



A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its position in shares of ADMA Biologics by 54.7% during the third quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock worth $1,422,000 after buying an additional 81,003 shares in the last quarter. Vanguard Group Inc. grew its position in shares of ADMA Biologics by 5.2% during the third quarter. Vanguard Group Inc. now owns 1,192,641 shares of the biotechnology company’s stock worth $7,406,000 after buying an additional 58,610 shares in the last quarter. Rhumbline Advisers grew its position in shares of ADMA Biologics by 50.5% during the fourth quarter. Rhumbline Advisers now owns 23,279 shares of the biotechnology company’s stock worth $56,000 after buying an additional 7,810 shares in the last quarter. BlackRock Inc. grew its position in shares of ADMA Biologics by 0.5% during the fourth quarter. BlackRock Inc. now owns 964,349 shares of the biotechnology company’s stock worth $2,305,000 after buying an additional 4,577 shares in the last quarter. Finally, Raymond James & Associates grew its position in shares of ADMA Biologics by 65.2% during the fourth quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock worth $64,000 after buying an additional 10,610 shares in the last quarter. Institutional investors own 38.70% of the company’s stock.

NASDAQ:ADMA traded down $0.07 during mid-day trading on Thursday, hitting $3.62. 4,339 shares of the company’s stock were exchanged, compared to its average volume of 1,051,140. ADMA Biologics has a one year low of $2.08 and a one year high of $6.96. The company has a debt-to-equity ratio of 5.70, a quick ratio of 2.39 and a current ratio of 4.60. The company has a fifty day moving average price of $4.18. The stock has a market cap of $208.22 million, a P/E ratio of -2.49 and a beta of 2.92.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.01. The business had revenue of $3.53 million during the quarter, compared to analysts’ expectations of $2.96 million. ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%. Equities analysts predict that ADMA Biologics will post -1.04 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: What is a stock buyback?

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.